Trending Stock News

PolyOne (POL) Reaches $46.67 52-Week High; Vertex Pharmaceuticals (VRTX) SI Decreased By 3.77%

The stock of PolyOne Corporation (NYSE:POL) hit a new 52-week high and has $50.87 target or 9.00% above today’s $46.67 share price. The 5 months bullish chart indicates low risk for the $3.77B company. The 1-year high was reported on Nov, 30 by Barchart.com. If the $50.87 price target is reached, the company will be worth $339.39M more. The stock increased 0.41% or $0.19 during the last trading session, reaching $46.67. About 78,928 shares traded. PolyOne Corporation (NYSE:POL) has risen 5.26% since November 30, 2016 and is uptrending. It has underperformed by 11.44% the S&P500.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) had a decrease of 3.77% in short interest. VRTX’s SI was 3.49M shares in November as released by FINRA. Its down 3.77% from 3.63M shares previously. With 1.94M avg volume, 2 days are for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s short sellers to cover VRTX’s short positions. The SI to Vertex Pharmaceuticals Incorporated’s float is 1.41%. The stock increased 0.66% or $0.95 during the last trading session, reaching $144.7. About 338,948 shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since November 30, 2016 and is uptrending. It has outperformed by 28.99% the S&P500.

Since June 1, 2017, it had 0 insider purchases, and 1 sale for $975,000 activity. 3,867 shares valued at $492,308 were sold by Silva Paul M on Thursday, June 1. Lee Yuchun also sold $169,926 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares. On Thursday, June 1 the insider Chodakewitz Jeffrey sold $654,015. 98,553 shares were sold by SMITH IAN F, worth $12.22M on Thursday, June 1. LEIDEN JEFFREY M sold $19.05 million worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Friday, June 2. Another trade for 7,500 shares valued at $975,000 was sold by ALTSHULER DAVID. 70,969 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares with value of $9.09M were sold by Arbuckle Stuart A.

Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases. The company has market cap of $36.60 billion. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs. It has a 139 P/E ratio. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.

Among 26 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 22 have Buy rating, 0 Sell and 4 Hold. Therefore 85% are positive. Vertex Pharmaceuticals had 77 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Perform” rating given on Thursday, February 11 by Oppenheimer. JMP Securities upgraded the stock to “Market Outperform” rating in Friday, March 17 report. As per Friday, October 2, the company rating was upgraded by Morgan Stanley. Maxim Group maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Wednesday, July 19 with “Buy” rating. The firm earned “Hold” rating on Wednesday, July 19 by UBS. On Tuesday, September 26 the stock rating was maintained by Leerink Swann with “Buy”. Janney Capital upgraded the shares of VRTX in report on Wednesday, July 19 to “Buy” rating. On Wednesday, July 19 the stock rating was upgraded by Barclays Capital to “Overweight”. On Friday, September 15 the stock rating was maintained by Needham with “Buy”. The firm has “Neutral” rating given on Thursday, April 28 by Goldman Sachs.

Investors sentiment increased to 1.51 in 2017 Q2. Its up 0.20, from 1.31 in 2017Q1. It is positive, as 31 investors sold Vertex Pharmaceuticals Incorporated shares while 154 reduced holdings. 98 funds opened positions while 181 raised stakes. 231.33 million shares or 0.08% less from 231.51 million shares in 2017Q1 were reported. Cannell Peter B And Incorporated reported 1,588 shares or 0.01% of all its holdings. Ubs Asset Management Americas Incorporated has invested 0% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The Illinois-based Envestnet Asset Management Inc has invested 0.01% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Redmile Group Incorporated Ltd Llc holds 144,408 shares. Stonebridge Cap Mngmt stated it has 3,972 shares or 0.2% of all its holdings. 907,109 were reported by Swiss Comml Bank. Moreover, Quantres Asset Limited has 0.67% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Canal Insur holds 1.88% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 40,000 shares. 47,821 are owned by Exxonmobil Invest Mngmt Inc Tx. Commonwealth Of Pennsylvania School Empls Retrmt System has invested 0.04% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Sumitomo Mitsui Trust Inc has 776,986 shares for 0.15% of their portfolio. Voya Invest Limited Liability Company reported 97,869 shares or 0.03% of all its holdings. Gsa Llp reported 19,023 shares. Wfg Ltd Partnership has invested 0% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Usa Fincl Portformulas stated it has 0.71% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Among 9 analysts covering Polyone Corporation (NYSE:POL), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Polyone Corporation had 23 analyst reports since July 28, 2015 according to SRatingsIntel. Oppenheimer initiated PolyOne Corporation (NYSE:POL) on Wednesday, August 16 with “Buy” rating. The rating was maintained by Jefferies with “Hold” on Friday, August 4. Jefferies maintained PolyOne Corporation (NYSE:POL) on Tuesday, October 17 with “Hold” rating. The stock of PolyOne Corporation (NYSE:POL) earned “Overweight” rating by KeyBanc Capital Markets on Thursday, October 26. Robert W. Baird maintained PolyOne Corporation (NYSE:POL) rating on Monday, August 24. Robert W. Baird has “Buy” rating and $39 target. Jefferies maintained PolyOne Corporation (NYSE:POL) rating on Friday, September 15. Jefferies has “Hold” rating and $42.0 target. The firm earned “Buy” rating on Tuesday, October 10 by Robert W. Baird. The stock of PolyOne Corporation (NYSE:POL) has “Overweight” rating given on Monday, April 4 by KeyBanc Capital Markets. Jefferies maintained it with “Hold” rating and $45.0 target in Wednesday, October 25 report. Seaport Global upgraded the shares of POL in report on Monday, April 18 to “Buy” rating.

Investors sentiment decreased to 0.93 in Q2 2017. Its down 0.18, from 1.11 in 2017Q1. It fall, as 32 investors sold PolyOne Corporation shares while 86 reduced holdings. 45 funds opened positions while 65 raised stakes. 73.89 million shares or 1.41% more from 72.86 million shares in 2017Q1 were reported. Dalton Greiner Hartman Maher & accumulated 399,301 shares. Mutual Of America Ltd Co holds 0.07% in PolyOne Corporation (NYSE:POL) or 104,554 shares. Bnp Paribas Arbitrage holds 0.01% or 43,455 shares in its portfolio. Wellington Management Group Limited Liability Partnership has invested 0.03% of its portfolio in PolyOne Corporation (NYSE:POL). Granahan Invest Ma holds 0.02% or 5,240 shares. Gsa Capital Prns Llp has 0.13% invested in PolyOne Corporation (NYSE:POL). Zurcher Kantonalbank (Zurich Cantonalbank) invested in 0% or 4,063 shares. Ameriprise Inc has invested 0.01% of its portfolio in PolyOne Corporation (NYSE:POL). Mufg Americas Holdings holds 1,750 shares. Public Employees Retirement System Of Ohio reported 7,516 shares. First Citizens Bancorp And owns 10,842 shares. Boston reported 201,624 shares. Pitcairn accumulated 10,078 shares or 0.05% of the stock. State Board Of Administration Of Florida Retirement Sys holds 0.01% or 84,231 shares in its portfolio. Washington Tru National Bank & Trust accumulated 2,830 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *